Atrium Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Atrium Therapeutics, Inc.'s yearly results, compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.9 times its market value (net cash). Higher than 95% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
—Data incomplete
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-11.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 53% of Healthcare companies in United States.
Cash Cushion Ratio
1.9× cashCash, after subtracting all debt, is 1.9 times its market value (net cash).
Higher than 95% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Atrium Therapeutics, Inc. made a loss over the last year. Atrium Therapeutics, Inc. owes $0.24 for every $1 it owns. Atrium Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAtrium Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.65The share price is 0.65 times Atrium Therapeutics, Inc.'s book value per share, lower than 87% of Healthcare companies in United States.
Market cap
$140 MThe total market value of all of Atrium Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$215 MWhat Atrium Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$12.54Net worth divided by the number of shares. The share price of $8.16 is 0.7 times this, which is the P/B above.
Owes vs Owns
0.24×Atrium Therapeutics, Inc. owes $0.24 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Dividend yield
NoneAtrium Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+71%Revenue rose 71% in the year to Dec 2025.
Profit growth
LossAtrium Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-411.9%Atrium Therapeutics, Inc. lost $412 for every $100 of revenue.
Cash vs debt
Net cashAtrium Therapeutics, Inc. held $266 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Atrium Therapeutics, Inc.: $140 M ÷ $215 M (30 Jun 2026) = 0.7.
How much does Atrium Therapeutics, Inc. owe compared with what it owns?
Atrium Therapeutics, Inc. owes $0.24 for every $1 it owns (low), lower than 68% of Healthcare companies in United States.
Does Atrium Therapeutics, Inc. pay a dividend?
No. Atrium Therapeutics, Inc. does not currently pay a dividend.
Is Atrium Therapeutics, Inc.'s revenue growing?
Revenue rose 71% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.